Autologous mesenchymal stem cells STR 01 co-developed with Sapporo Medical University. may be a magic bullet for spinal damage. The cellular drug obtained Sakigake designation for accelerated examination, in February 2016, patients with spinal cord injury received treatment, and Nipro filed for conditional market approval on June 29th 2018.
Nipro news release, July 3, 2018
Nipro applies for approval of mesenchymal stem cells STR 01 for treatment of spinal damage